Novo Nordisk A/S (NYSE:NVO) Shares Bought by A. D. Beadell Investment Counsel Inc.

A. D. Beadell Investment Counsel Inc. increased its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 35.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,585 shares of the company's stock after purchasing an additional 4,573 shares during the quarter. A. D. Beadell Investment Counsel Inc.'s holdings in Novo Nordisk A/S were worth $1,221,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in NVO. Stablepoint Partners LLC grew its stake in shares of Novo Nordisk A/S by 55.8% during the first quarter. Stablepoint Partners LLC now owns 18,798 shares of the company's stock valued at $1,305,000 after acquiring an additional 6,730 shares in the last quarter. Atwater Malick LLC boosted its holdings in Novo Nordisk A/S by 1.0% in the first quarter. Atwater Malick LLC now owns 163,869 shares of the company's stock valued at $11,379,000 after purchasing an additional 1,641 shares during the last quarter. Curat Global LLC acquired a new stake in Novo Nordisk A/S during the 1st quarter valued at approximately $266,000. Signal Advisors Wealth LLC raised its position in shares of Novo Nordisk A/S by 1.6% in the 1st quarter. Signal Advisors Wealth LLC now owns 16,123 shares of the company's stock valued at $1,120,000 after purchasing an additional 249 shares in the last quarter. Finally, Foster Group Inc. purchased a new position in shares of Novo Nordisk A/S during the 1st quarter valued at approximately $216,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $72.57 on Friday. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The stock has a fifty day moving average price of $65.73 and a 200 day moving average price of $80.90. The company has a market cap of $325.64 billion, a P/E ratio of 22.06, a PEG ratio of 0.90 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The business had revenue of $11.87 billion during the quarter. On average, research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Wall Street Analyst Weigh In

NVO has been the subject of a number of research analyst reports. BMO Capital Markets restated a "market perform" rating and issued a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Wall Street Zen raised shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 25th. Dbs Bank lowered Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Finally, BNP Paribas began coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They set an "underperform" rating on the stock. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, four have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Novo Nordisk A/S presently has an average rating of "Hold" and a consensus target price of $128.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.